Bronchiolo-Alveolar Adenocarcinoma

This is a type of lung cancer that starts in the small airways (bronchioles) and the air sacs (alveoli) in the lungs. It's a specific subtype of adenocarcinoma, meaning it starts in the cells that line glands.

Condition

What people with Bronchiolo-Alveolar Adenocarcinoma report

Every report comes from a Lived member, sent anonymously.

Have you had Lung Surgery for Bronchiolo-Alveolar Adenocarcinoma?

NameHow it went

About Bronchiolo-Alveolar Adenocarcinoma

What It Is

Bronchiolo-alveolar adenocarcinoma, often shortened to BAC, is an older name for a group of lung cancers that start in the cells lining the smallest airways and air sacs. Many of these tumors spread out along the inner walls of the air sacs, like a thin coating, rather than forming a solid lump that pushes into surrounding tissue. They belong to adenocarcinoma, the most common type of non-small cell lung cancer. In 2011, international lung cancer, chest medicine and respiratory societies stopped using the term, because it had been applied to tumors with very different outlooks. Doctors now use more precise names. Adenocarcinoma in situ is a small tumor that has not invaded at all. Minimally invasive adenocarcinoma has invaded no more than 5 millimeters. Lepidic predominant adenocarcinoma is an invasive cancer that still grows mostly along the air sac walls. Invasive mucinous adenocarcinoma, formerly mucinous BAC, is made of mucus-producing cells and often spreads through several areas of the lung. If an older report or a family member's records say BAC, it is worth asking which of these your diagnosis corresponds to, since that shapes treatment and outlook.

Causes & Risk Factors

Smoking is the major risk factor for non-small cell lung cancer, including adenocarcinoma. Secondhand smoke, radon in the home or workplace, workplace exposures such as asbestos, air pollution, earlier radiation to the chest and a family history of lung cancer also raise risk. These tumors also develop in people who have never smoked. The mucinous type in particular is less strongly tied to tobacco than other lung cancers, and a substantial share of people with it never smoked or smoked very little. Its other causes are not well understood. Having a risk factor does not mean someone will develop lung cancer, and many people diagnosed have no known risk factor at all.

How It's Diagnosed

Many of these cancers cause no symptoms early and are found on a CT scan done for another reason or for lung cancer screening. On CT (computed tomography, a detailed X-ray scan), the slowest-growing forms usually appear as a ground-glass nodule: a small hazy spot through which normal blood vessels can still be seen. A part-solid nodule has both hazy and dense areas, and a solid nodule hides the structures behind it. A denser, solid portion tends to correspond to invasive tumor, so radiologists track both size and density. Because a purely hazy nodule grows very slowly and can have harmless causes, doctors often repeat the CT over months to years before deciding to remove it. Growth or a new solid area suggests the tumor is becoming invasive. The mucinous type behaves differently. It may cause a lingering cough with large amounts of clear or white sputum, and on imaging it often looks like pneumonia. When an area of apparent pneumonia does not clear with antibiotics, or keeps returning in the same place, doctors consider this cancer and seek a tissue sample. A tissue sample is needed to confirm cancer, taken by a needle through the chest wall, through a bronchoscope (a thin tube passed into the airways) or during surgery. The in situ and minimally invasive types can only be confirmed after the entire tumor has been removed and examined, because a small biopsy cannot show whether invasion is present elsewhere in the tumor. Further scans and sometimes lymph node sampling determine the stage, meaning how far the cancer has spread. For more advanced cancer, the tumor is tested for biomarkers, specific genetic changes such as mutations in the EGFR gene (epidermal growth factor receptor), that point to targeted treatments.

Treatment Options

For cancer confined to the lung, surgery offers the best chance of cure. Surgeons remove either the whole lobe (one of the large sections of the lung) or a smaller wedge or segment. For a peripheral tumor 2 centimeters or smaller with no lymph node spread, a large trial found that removing the smaller portion controlled the cancer as well as removing the whole lobe, with similar survival and slightly better preserved breathing. When the in situ or minimally invasive types are completely removed, essentially no one dies of that cancer. People who cannot have surgery may be offered stereotactic body radiation therapy, which delivers high, precisely aimed doses over a few sessions. When the cancer is invasive and larger, has reached lymph nodes or has spread, treatment follows the general approach for non-small cell lung cancer and depends on stage, overall health and preference. It can combine surgery, radiation, chemotherapy, targeted therapy and immunotherapy (medicines that help the immune system attack cancer). Targeted drugs work against tumors with particular genetic changes, such as an EGFR mutation or ALK rearrangement, which is why biomarker testing matters before choosing treatment. Advanced invasive mucinous adenocarcinoma is harder to treat. It frequently carries a KRAS mutation, for which broadly effective targeted options are more limited, and it tends to respond less well to immunotherapy than other adenocarcinomas. People with widespread or multifocal disease may want to ask about clinical trials.

What to Expect

The outlook depends far more on which type and stage of tumor someone has than on the old BAC label. Small in situ and minimally invasive tumors that are completely removed are effectively cured. Invasive lepidic predominant cancers found early also tend to do well after surgery. Early, localized mucinous tumors can do well after surgery too, but when the mucinous type is spread through much of the lung or has advanced, it can progress quickly and treatment options are limited. After treatment, follow-up CT scans are part of life for years afterward, both to check for recurrence and because people with one adenocarcinoma can develop others: in surgical series, up to about a fifth of patients have more than one separate lung adenocarcinoma. Some people live for long periods with several small hazy nodules that are watched rather than removed, which can be unsettling; a clear plan for which nodules are being tracked and why helps. For anyone who smokes, stopping improves lung health and recovery and lowers the risk of new cancers.

When to Seek Help

Arrange a visit to discuss any lung nodule found on a scan, so that you understand whether it needs follow-up imaging, a biopsy or removal, and keep to the agreed scan schedule. See a doctor about a cough that does not go away or keeps worsening, persistent large amounts of sputum, or pneumonia that does not clear with antibiotics or returns in the same part of the lung. Contact your care team promptly if you cough up blood, if shortness of breath worsens noticeably, or if you lose weight without trying, whether or not you have already been diagnosed or treated.

Questions to Ask Your Doctor

  1. 1.Under the current classification, which type of adenocarcinoma do I have, and what stage is it?
  2. 2.Does my nodule need surgery now, or is it reasonable to monitor it with CT scans, and what changes would make you recommend removal?
  3. 3.If I have surgery, would removing a smaller part of the lung be enough, and how would each option affect my breathing?
  4. 4.Has my tumor been tested for biomarkers such as EGFR, ALK or KRAS, and how do the results change my treatment options?
  5. 5.How often will I need follow-up scans, and what will we do if new nodules appear?

Last reviewed • Oct 2026

Educational content, not medical advice.